Company at a Glance

Itamar Medical Ltd., is a public traded (TASE: ITMR) bio-medical technology company. Itamar develops and markets noninvasive diagnostic medical equipment based on proprietary PAT™ (Peripheral Arterial Tone) Signal. The PAT™ Signal serves as a noninvasive window to the Cardiovascular and Autonomic Nervous Systems.
The PAT Signal is acquired by measuring pulsatile arterial volume changes in the fingertip by specialized noninvasive probes. Itamar’s FDA cleared & CE marked PAT-based products are:

• Endo-PAT2000: noninvasive, office-based, user-independent device for endothelial function assessment – the precursor (earliest clinically detectable stage) of cardiovascular disease.
• Watch-PAT200: ambulatory diagnosis of sleep related breathing disorders and sleep staging (Wake/REM/Deep sleep/light sleep stages).

Both devices are used in preeminent clinical institutions, research centers and Pharmaceutical clinical phase studies in over 40 countries which have yielded nearly 300 publications.

Technology & Product(s)

Sleep testing – at home

Considered “best in class”, WatchPAT (FDA cleared & CE marked) is a wrist mounted device for at-home testing of sleep apneas and sleep staging (REM/Deep Sleep/Light Sleep/Wake stages). WatchPAT also measures snoring & body position and provides a perfect combination of natural sleep at home with sleep-lab level data.
WatchPAT works without the multiple cables and electrodes needed by other technologies which provide in-depth analysis of sleep, so it has an incredibly low failure rate. Yet the physician gets a comprehensive report with all the clinical parameters needed for patient treatment and monitoring. While the data is calculated automatically by the WatchPAT’s software, the physician can easily edit the data too.

Noninvasive cardiovascular risk assessment

Atherosclerosis is the clinical manifestation of endothelial dysfunction. Leading the field of endothelial function assessment, EndoPAT (FDA cleared & CE marked) is used in pre-eminent clinical institutions, research centers and Pharma studies. The noninvasive EndoPAT has been validated by nearly 100 publications and abstracts and provides clinicians with reliable and reproducible results in an office-based, 15 minute test.

Goal

Objectives: Establish wide distribution network in Europe
Target businesses: Distribution
Target Countries: Germany, UK, Spain, France , Scandinavia, Russia, Ukraine, China, India